Integrated Diagnostics Launches Spin-out InDi Molecular to Commercialize PCC Reagents | GenomeWeb

Integrated Diagnostics said this week that it has spun out its protein catalyzed capture agent business into a new firm, InDi Molecular.

The new outfit, which aims to market its PCC agents as alternatives to antibodies for use in the in vivo imaging, therapeutic, in vitro diagnostic, and biological tools markets, launched with $1.5 million in seed funding from InterWest Partners and company co-founders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.